Dietary interventions and vitamin D3 replacement in pituitary tumors: a systematic review
- 28 August 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (3) , S23-S35
Abstract
Objectives: Pituitary neuroendocrine tumors (PitNETs) cause hormonal imbalances that impair metabolic health and quality of life (QoL). Dietary interventions may mitigate these comorbidities. This review evaluated the effectiveness of dietary strategies in improving disease-related metabolic and bone outcomes in patients with PitNETs. Design: Systematic review of interventional and observational studies on dietary interventions in acromegaly, Cushing's disease (CD), prolactinomas, and hypopituitarism (HP). Methods: A systematic search was performed on January 20, 2026. Eligible studies assessed dietary interventions targeting metabolic or bone-related outcomes. Risk of bias was evaluated using ROBINS-I and the Newcastle–Ottawa Scale. Extracted outcomes included dietary intake, body composition, metabolic parameters, biochemical control, and bone health. Results: Of 2256 screened records, 8 studies (355 participants) met the inclusion criteria, including 5 interventional and 3 observational studies. In acromegaly, an isocaloric very-low-carbohydrate ketogenic diet (VLCKD) reduced insulin-like growth factor 1 (IGF-I) levels. In CD, VLCKD and energy-restricted diets (ERD) improved BMI and metabolic parameters. In prolactinoma, ERD combined with increased physical activity improved weight and biochemical control. In HP, ERD with increased physical activity and sibutramine improved body composition and metabolic outcomes. Vitamin D replacement reduced vertebral fracture risk in acromegaly and improved insulin sensitivity and lipid levels in CD. Conclusions: Evidence on dietary strategies for PitNET management is limited. Low-carbohydrate diet and ERD may improve adverse metabolic comorbidities, while vitamin D3 replacement shows potential benefits for insulin sensitivity in CD and fracture risk in acromegaly. Larger randomized trials are needed to confirm effects on disease control, comorbidities, and QoL.Keywords
Funding Information
- Erasmus MC Fellowship (EP22.0382)
This publication has 56 references indexed in Scilit:
- Impact of nutrient intake on bone mineral density and bone quality in patients with acromegalyClinical Nutrition ESPEN, 2025
- Effect of ketogenic diets on insulin-like growth factor (IGF)-1 in humans: A systematic review and meta-analysisAgeing Research Reviews, 2024
- Acromegaly and the long-term fracture risk of the vertebra and hip: a national cohort studyOsteoporosis International, 2023
- Characterization of vitamin D metabolism in active acromegaly in the setting of bolus (150,000 IU) cholecalciferol treatmentEndocrine, 2022
- Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: The Rotterdam StudyBone, 2018
- Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegalyJournal of the Formosan Medical Association, 2018
- Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide studyEndocrine, 2016
- Effects of growth hormone–releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studiesGrowth Hormone & IGF Research, 2015
- Vitamin D deficiency as a risk factor for osteoporotic fracturesBone, 2008
- Glucose but Not Protein or Fat Load Amplifies the Cortisol Response to Psychosocial StressHormones and Behavior, 2002